CA2399548A1 - Peptides liberant l'hormone de croissance comme modulateurs negatifs de l'atherosclerose et de l'hypercholesterolemie - Google Patents
Peptides liberant l'hormone de croissance comme modulateurs negatifs de l'atherosclerose et de l'hypercholesterolemie Download PDFInfo
- Publication number
- CA2399548A1 CA2399548A1 CA002399548A CA2399548A CA2399548A1 CA 2399548 A1 CA2399548 A1 CA 2399548A1 CA 002399548 A CA002399548 A CA 002399548A CA 2399548 A CA2399548 A CA 2399548A CA 2399548 A1 CA2399548 A1 CA 2399548A1
- Authority
- CA
- Canada
- Prior art keywords
- ghrp
- ghrps
- macrophages
- atherosclerosis
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 title claims abstract description 39
- 102100033367 Appetite-regulating hormone Human genes 0.000 title claims abstract description 38
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 19
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 8
- 102000053028 CD36 Antigens Human genes 0.000 claims abstract description 26
- 108010045374 CD36 Antigens Proteins 0.000 claims abstract description 26
- 230000003902 lesion Effects 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims abstract description 16
- HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 claims abstract description 12
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 7
- 102000014452 scavenger receptors Human genes 0.000 claims abstract description 7
- 108010078070 scavenger receptors Proteins 0.000 claims abstract description 7
- RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 claims abstract description 6
- 108010070965 hexarelin Proteins 0.000 claims abstract description 6
- 238000011161 development Methods 0.000 claims description 18
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 claims description 5
- 230000003143 atherosclerotic effect Effects 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 3
- 239000000816 peptidomimetic Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 88
- 241000699670 Mus sp. Species 0.000 abstract description 56
- 210000002540 macrophage Anatomy 0.000 abstract description 29
- 235000012000 cholesterol Nutrition 0.000 abstract description 28
- 235000005911 diet Nutrition 0.000 abstract description 28
- 230000037213 diet Effects 0.000 abstract description 27
- 230000002829 reductive effect Effects 0.000 abstract description 17
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 210000000497 foam cell Anatomy 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 abstract description 9
- 102100039256 Growth hormone secretagogue receptor type 1 Human genes 0.000 abstract description 8
- 101710202385 Growth hormone secretagogue receptor type 1 Proteins 0.000 abstract description 8
- 210000001616 monocyte Anatomy 0.000 abstract description 8
- 229960000208 pralmorelin Drugs 0.000 abstract description 8
- 102000004895 Lipoproteins Human genes 0.000 abstract description 6
- 108090001030 Lipoproteins Proteins 0.000 abstract description 6
- 210000003200 peritoneal cavity Anatomy 0.000 abstract description 6
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 abstract description 4
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 abstract description 4
- 108010071584 oxidized low density lipoprotein Proteins 0.000 abstract description 4
- 108010069113 somatocrinin receptor Proteins 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 abstract description 2
- 101710095339 Apolipoprotein E Proteins 0.000 abstract description 2
- 102100029470 Apolipoprotein E Human genes 0.000 abstract description 2
- 200000000007 Arterial disease Diseases 0.000 abstract description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 abstract description 2
- RVKIPWVMZANZLI-ZFWWWQNUSA-N Lys-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-ZFWWWQNUSA-N 0.000 abstract description 2
- 102400000988 Met-enkephalin Human genes 0.000 abstract description 2
- 108010042237 Methionine Enkephalin Proteins 0.000 abstract description 2
- 108010087066 N2-tryptophyllysine Proteins 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 230000001817 pituitary effect Effects 0.000 abstract description 2
- 230000002000 scavenging effect Effects 0.000 abstract description 2
- 230000003248 secreting effect Effects 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 230000028550 monocyte chemotaxis Effects 0.000 abstract 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 31
- 108010025628 Apolipoproteins E Proteins 0.000 description 31
- 230000018109 developmental process Effects 0.000 description 16
- 230000035508 accumulation Effects 0.000 description 14
- 238000009825 accumulation Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000002950 deficient Effects 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 235000021590 normal diet Nutrition 0.000 description 8
- 210000003024 peritoneal macrophage Anatomy 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 6
- 108010051696 Growth Hormone Proteins 0.000 description 5
- 102100038803 Somatotropin Human genes 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000122 growth hormone Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 230000006372 lipid accumulation Effects 0.000 description 4
- 102000004311 liver X receptors Human genes 0.000 description 4
- 108090000865 liver X receptors Proteins 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101000603962 Homo sapiens Oxysterols receptor LXR-alpha Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 102100038476 Oxysterols receptor LXR-alpha Human genes 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 101150092476 ABCA1 gene Proteins 0.000 description 2
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000000393 Ghrelin Receptors Human genes 0.000 description 2
- 108010016122 Ghrelin Receptors Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 210000002168 brachiocephalic trunk Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000026758 coronary atherosclerosis Diseases 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000037189 immune system physiology Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003578 releasing effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102100021242 Dymeclin Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 description 1
- 206010051124 Hyperfibrinogenaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000000778 atheroprotective effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000191 macrophage derived foam cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000009024 positive feedback mechanism Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002399548A CA2399548A1 (fr) | 2002-08-23 | 2002-08-23 | Peptides liberant l'hormone de croissance comme modulateurs negatifs de l'atherosclerose et de l'hypercholesterolemie |
| PCT/GB2003/003669 WO2004017986A1 (fr) | 2002-08-23 | 2003-08-21 | Peptides liberant l'hormone de croissance pour le traitement ou la prevention de l'atherosclerose et de l'hypercholesterolemie |
| JP2005501218A JP2005539091A (ja) | 2002-08-23 | 2003-08-21 | アテローム性動脈硬化および高コレステロール血症の治療または予防における成長ホルモン放出ペプチド類 |
| EP03792511A EP1536817A1 (fr) | 2002-08-23 | 2003-08-21 | Peptides liberant l'hormone de croissance pour le traitement ou la prevention de l'atherosclerose et de l'hypercholesterolemie |
| US10/525,266 US7785567B2 (en) | 2002-08-23 | 2003-08-21 | Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia |
| AU2003259340A AU2003259340A1 (en) | 2002-08-23 | 2003-08-21 | Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002399548A CA2399548A1 (fr) | 2002-08-23 | 2002-08-23 | Peptides liberant l'hormone de croissance comme modulateurs negatifs de l'atherosclerose et de l'hypercholesterolemie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2399548A1 true CA2399548A1 (fr) | 2004-02-23 |
Family
ID=31983598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002399548A Abandoned CA2399548A1 (fr) | 2002-08-23 | 2002-08-23 | Peptides liberant l'hormone de croissance comme modulateurs negatifs de l'atherosclerose et de l'hypercholesterolemie |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2399548A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008154738A1 (fr) * | 2007-06-18 | 2008-12-24 | Universite De Montreal | Azapeptides comme composés se liant au cd36 |
| CN110882378A (zh) * | 2018-09-10 | 2020-03-17 | 上海清流生物医药科技有限公司 | 一种蛋白在制备预防和治疗动脉粥样硬化及并发症药物的应用 |
| US11879021B2 (en) | 2016-06-28 | 2024-01-23 | Université de Montréal | Cyclic peptides and uses thereof |
-
2002
- 2002-08-23 CA CA002399548A patent/CA2399548A1/fr not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008154738A1 (fr) * | 2007-06-18 | 2008-12-24 | Universite De Montreal | Azapeptides comme composés se liant au cd36 |
| US8435954B2 (en) | 2007-06-18 | 2013-05-07 | Valorisation-Recherche, Limited Partnership | Azapeptides as CD36 binding compounds |
| US9115171B2 (en) | 2007-06-18 | 2015-08-25 | Valorisation-Recherche, Limited Partnership | Azapeptides as CD36 binding compounds |
| US9708370B2 (en) | 2007-06-18 | 2017-07-18 | Valorisation-Recherche, Limited Partnership | Azapeptides as CD36 binding compounds |
| US11879021B2 (en) | 2016-06-28 | 2024-01-23 | Université de Montréal | Cyclic peptides and uses thereof |
| CN110882378A (zh) * | 2018-09-10 | 2020-03-17 | 上海清流生物医药科技有限公司 | 一种蛋白在制备预防和治疗动脉粥样硬化及并发症药物的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marleau et al. | EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E‐deficient mice from developing atherosclerotic lesions | |
| ES2210800T3 (es) | Uso de receptores solubles para productos finales de glicacion avanzada (srage) para prevenir la aterosclerosis acelerada. | |
| Taub | Novel connections between the neuroendocrine and immune systems: the ghrelin immunoregulatory network | |
| Chait et al. | Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease | |
| US20170151313A1 (en) | Lipid hydrolysis therapy for atherosclerosis and related diseases | |
| US20100047330A1 (en) | Treatment for dark adaptation | |
| US20090305964A1 (en) | Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug | |
| Torsello et al. | Ghrelin plays a minor role in the physiological control of cardiac function in the rat | |
| US7592305B2 (en) | Use of ghrelin for treating malnutrition in gastrectomized individuals | |
| US7785567B2 (en) | Growth hormone-releasing peptides in the treatment or prevention of atherosclerosis and hypercholesterolemia | |
| JP2011042688A (ja) | 摂食行動の修正 | |
| Stenger et al. | Up‐regulation of hepatic lipolysis stimulated lipoprotein receptor by leptin: a potential lever for controlling lipid clearance during the postprandial phase | |
| Peskar | Neural aspects of prostaglandin involvement in gastric mucosal defense | |
| JP6772317B2 (ja) | アポリポタンパク質模倣体及びその使用 | |
| CA2399548A1 (fr) | Peptides liberant l'hormone de croissance comme modulateurs negatifs de l'atherosclerose et de l'hypercholesterolemie | |
| Udenigwe et al. | Hypolipidemic and hypocholesterolemic food proteins and peptides | |
| Ochiai et al. | Egg white hydrolysate improves glucose tolerance in type-2 diabetic NSY mice | |
| Kajani et al. | Sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates IL-1β secretion from adipose tissue: The implications for obesity-impaired reverse cholesterol transport | |
| Navab et al. | Apo A-1 mimetic peptides as atheroprotective agents in murine models | |
| US20110135661A1 (en) | Treatment and prevention of dry age-related macular degeneration by activating cd36 | |
| Alba et al. | Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse | |
| Hedner et al. | ANP—a cardiac hormone and a putative central neurotransmitter | |
| Moore et al. | Macrophage foam cell formation: the pathways to cholesterol engorgement | |
| Owyang | Discovery of a cholecystokinin-releasing peptide: biochemical characterization and physiological implications | |
| EP4360643A1 (fr) | Peptides dérivés de socs1 destinés à être utilisés dans le traitement de maladies hépatiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |